Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Shaw

Showing results (131-140 of 142) with videos related to

Pageof 15
Sort By:
Nature Chemical Biology|October 18, 2018
Structural insights into binding specificity, efficacy and bias of a β<sub>2</sub>AR partial agonistMatthieu Masureel, Yaozhong Zou, Louis-Philippe Picard, et al.
Nature Chemical Biology|December 4, 2018
Publisher Correction: Structural insights into binding specificity, efficacy and bias of a β<sub>2</sub>AR partial agonistMatthieu Masureel, Yaozhong Zou, Louis-Philippe Picard, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 2, 2017
Atomic structure of a toxic, oligomeric segment of SOD1 linked to amyotrophic lateral sclerosis (ALS)Smriti Sangwan, Anni Zhao, Katrina L Adams, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 24, 2012
Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibodyAaron G Schmidt, Huafeng Xu, Amir R Khan, et al.
Nature|January 14, 2011
Structure and function of an irreversible agonist-β(2) adrenoceptor complexDaniel M Rosenbaum, Cheng Zhang, Joseph A Lyons, et al.
Nature Communications|November 1, 2016
EGFR oligomerization organizes kinase-active dimers into competent signalling platformsSarah R Needham, Selene K Roberts, Anton Arkhipov, et al.
Nature Communications|October 20, 2018
The architecture of EGFR's basal complexes reveals autoinhibition mechanisms in dimers and oligomersLaura C Zanetti-Domingues, Dimitrios Korovesis, Sarah R Needham, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 1, 2024
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2Heike Schönherr, Pelin Ayaz, Alexander M Taylor, et al.
Cancer Discovery|June 4, 2023
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance MutationsVivek Subbiah, Vaibhav Sahai, Dejan Maglic, et al.
Journal of Medicinal Chemistry|September 29, 2023
Identification of GDC-1971 (RLY-1971), a SHP2 Inhibitor Designed for the Treatment of Solid TumorsAlexander M Taylor, Bret R Williams, Fabrizio Giordanetto, et al.
Pageof 15

Showing results (131-140 of 142) with videos related to

Sort By:
Pageof 15
Nature Chemical Biology|October 18, 2018
Structural insights into binding specificity, efficacy and bias of a β<sub>2</sub>AR partial agonistMatthieu Masureel, Yaozhong Zou, Louis-Philippe Picard, et al.
Nature Chemical Biology|December 4, 2018
Publisher Correction: Structural insights into binding specificity, efficacy and bias of a β<sub>2</sub>AR partial agonistMatthieu Masureel, Yaozhong Zou, Louis-Philippe Picard, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 2, 2017
Atomic structure of a toxic, oligomeric segment of SOD1 linked to amyotrophic lateral sclerosis (ALS)Smriti Sangwan, Anni Zhao, Katrina L Adams, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 24, 2012
Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibodyAaron G Schmidt, Huafeng Xu, Amir R Khan, et al.
Nature|January 14, 2011
Structure and function of an irreversible agonist-β(2) adrenoceptor complexDaniel M Rosenbaum, Cheng Zhang, Joseph A Lyons, et al.
Nature Communications|November 1, 2016
EGFR oligomerization organizes kinase-active dimers into competent signalling platformsSarah R Needham, Selene K Roberts, Anton Arkhipov, et al.
Nature Communications|October 20, 2018
The architecture of EGFR's basal complexes reveals autoinhibition mechanisms in dimers and oligomersLaura C Zanetti-Domingues, Dimitrios Korovesis, Sarah R Needham, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 1, 2024
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2Heike Schönherr, Pelin Ayaz, Alexander M Taylor, et al.
Cancer Discovery|June 4, 2023
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance MutationsVivek Subbiah, Vaibhav Sahai, Dejan Maglic, et al.
Journal of Medicinal Chemistry|September 29, 2023
Identification of GDC-1971 (RLY-1971), a SHP2 Inhibitor Designed for the Treatment of Solid TumorsAlexander M Taylor, Bret R Williams, Fabrizio Giordanetto, et al.
Pageof 15